Evidence map›Paper›PMID 41053004›Full record

Trial reportBlood cancer journal2025

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Laahn Foster, Larry D Anderson, Alfred Chung, Chakra P Chaulagain, Erin Pettijohn, Andrew J Cowan, Caitlin Costello, Sarah Larson, Douglas W Sborov, Kenneth H Shain and 10 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03901963 (A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant), which is not on this map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03901963 phase3completednot on this map

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant

TypeinterventionalSponsorJanssen Research & Development, LLCRan2019 to 2026Enrolled200ConditionsMultiple MyelomaArmsDaratumumab, Lenalidomide
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Laahn FosterDivision of Hematology Oncology, University of Virginia, Charlottesville, VA, USA. LF5V@uvahealth.org.ORCID 0000-0001-8782-1634
Larry D AndersonMyeloma, Waldenstrom's and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.ORCID 0000-0002-6531-9595
Alfred ChungDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Chakra P ChaulagainDepartment of Hematology and Oncology, Myeloma and Amyloidosis Program, Cleveland Clinic Florida, Weston, FL, USA.ORCID 0000-0002-4641-2217
Erin PettijohnCancer and Hematology Centers of Western Michigan, Grand Rapids, MI, USA.
Andrew J CowanDivision of Medical Oncology, Fred Hutch Cancer Center/University of Washington, Seattle, WA, USA.
Caitlin CostelloMoores Cancer Center, University of California San Diego, La Jolla, CA, USA.
Sarah LarsonDivision of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
Douglas W SborovHuntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0003-4268-2698
Kenneth H ShainDepartment of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Rebecca SilbermannKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Peter VoorheesLevine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA.ORCID 0000-0003-1661-718X
Maria KrevvataJohnson & Johnson, Spring House, PA, USA.
Huiling PeiJohnson & Johnson, Titusville, NJ, USA.
Sharmila PatelJohnson & Johnson, Horsham, PA, USA.
Vipin KhareJohnson & Johnson, Horsham, PA, USA.
Annelore CortoosJohnson & Johnson, Horsham, PA, USA.
Robin CarsonJohnson & Johnson, Spring House, PA, USA.
Thomas S LinJohnson & Johnson, Horsham, PA, USA.
Ashraf BadrosGreenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA.

Funding

UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Sandi Leigh Pruitt · 2010 to 2026
$53.7M
NCI NIH HHS P30 CA142543
6 · The paper itself

Abstract

In the primary analysis (32.3-month median follow-up) of the randomized, phase 3 AURIGA study (NCT03901963), daratumumab-lenalidomide (D-R) maintenance significantly improved MRD-negative conversion rates and reduced the risk of disease progression or death by 47% versus R maintenance in anti-CD38 monoclonal antibody-naïve and post-transplant MRD-positive patients with newly diagnosed MM. Here, we present a post hoc analysis across relevant subgroups, including high-risk cytogenetic abnormalities (HRCAs) per original, revised, and modified International Myeloma Society (IMS) 2024 criteria. MRD-negative (10

Indexed as

Antibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsHematopoietic Stem Cell TransplantationLenalidomideMultiple MyelomaAdultAgedFemaleHumansMaintenance ChemotherapyMaleMiddle AgedAntibodies, MonoclonaldaratumumabLenalidomide

Identifiers

PMID41053004
PMCPMC12500855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.